Syndax Pharmaceuticals (SNDX) Net Equity Issued and Repurchased (2015 - 2023)

Syndax Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $216.0 million for Q4 2023.

• On a quarterly basis, Net Equity Issued and Repurchased rose 33.31% year-over-year to $216.0 million in Q4 2023; TTM through Dec 2023 was $378.0 million, a 55.41% increase from a year earlier, with the FY2023 full-year figure at $216.0 million, up 1011.74% from the prior year.
• Net Equity Issued and Repurchased improved to $216.0 million in Q4 2023 per SNDX's latest filing, from $162.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $216.0 million in Q4 2023 and bottomed at -$69.9 million in Q2 2021.
• The 5-year median for Net Equity Issued and Repurchased is $54.9 million (2020), against an average of $59.7 million.
• Across the five-year window, Net Equity Issued and Repurchased slumped 538.17% in 2019 and soared 359570.0% in 2020, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$26.5 million in 2019, then surged by 608.49% to $135.0 million in 2020, then plunged by 39.85% to $81.2 million in 2021, then surged by 99.51% to $162.0 million in 2022, then soared by 33.31% to $216.0 million in 2023.
• Per Business Quant, the three latest SNDX Net Equity Issued and Repurchased figures stand at $216.0 million (Q4 2023), $162.0 million (Q4 2022), and $81.2 million (Q4 2021).